Drug profile · INN
sutimlimab
ENJAYMO
sutimlimab (ENJAYMO) is a complement c1s inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AJ04
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — sutimlimab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
sutimlimab (ENJAYMO) is a complement c1s inhibitor.
Key facts
INN sutimlimab
Brand ENJAYMO
Mechanism Complement C1s inhibitor
Target Complement C1s subcomponent
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AJ04
Mechanism of action
Complement C1s inhibitor
Primary target: Complement C1s subcomponent
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is sutimlimab?
sutimlimab (ENJAYMO) is a complement c1s inhibitor.
What is the brand name for sutimlimab?
ENJAYMO is a marketed brand name for sutimlimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.